Here’s a tight weekly roundup mixing tech and biomed—headlines link out.
• Pfizer wins $10B fight for obesity-drug startup Metsera
A decisive move into the GLP-1 race, giving Pfizer a fresh shot at weight-loss medicines after setbacks in its own pipeline.
• CRISPR therapy slashes LDL and triglycerides in patients
Early human data show big lipid drops; the companion paper details outcomes and safety endpoints in NEJM.
• Personalized gene editing that helped one child now headed to a clinical trial
Researchers are adapting bespoke edits for multiple kids with ultra-rare mutations, testing how scalable “one-off” cures can be.
• “CRISPR babies” debate reignites as a company floats embryo editing plans
A Nature report surveys scientists’ reactions and the shifting ethical landscape around heritable genome editing.
• Braveheart Bio raises $185M to run late-stage trial for hypertrophic cardiomyopathy drug
Big financing to press a global pivotal program in a genetic heart disease with few options.
• Colossal buys animal-cloning firm Viagen to fuel de-extinction push
A biotech-meets-frontier-tech gamble that raises fresh scientific and ethical questions.
• Evolocumab shows benefit in high-risk patients without prior heart attack
New randomized data add clinical texture to PCSK9 inhibition’s role alongside statins.
• FDA updates guidance around Regenerative Medicine Advanced Therapy (RMAT) designation
A timely primer for cell- and gene-therapy sponsors navigating expedited pathways.
• WHO flags priorities and pressures in global immunization
SAGE notes funding gaps and trust erosion while countries scale newer vaccines.
• DeepMind: new AI tools to map species, predict deforestation, and parse biosignals
Fresh research threads AI into biodiversity modeling and environmental health surveillance.